Literature DB >> 1325026

IgM neutralizing antibody responses to human herpesvirus-6 in patients with exanthem subitum or organ transplantation.

S Suga1, T Yoshikawa, Y Asano, T Nakashima, T Yazaki, M Fukuda, S Kojima, T Matsuyama, Y Ono, S Oshima.   

Abstract

The assay for detecting IgM neutralizing (NT) antibody activity to human herpesvirus-6 (HHV-6) was developed by using pretreatment of blood sample with staphylococcal protein A. The activity was mostly present in IgM fractions of serum but not in IgA fractions separated by ultracentrifugation. The assay was used for seroepidemiological studies for HHV-6 infection. In primary HHV-6 infection, IgM NT antibodies appeared 5 to 7 days after onset of exanthem subitum, reached maximum titers at 2 to 3 weeks, and tended to decline to undetectable levels after 2 months. In contrast, reactivation of HHV-6 observed in organ transplants showed somewhat greater degree of IgM NT antibody responses that persisted for 2 to 3 months and became undetectable 5 to 6 months after transplantation. The level and persistence of NT antibody titers measured by the conventional method was generally greater than those of the IgM titers. The prevalence of the IgM NT antibodies was examined in healthy individuals. The antibody was first detected at 4 to 7 months of age (5%), reached maximum level at 8 to 11 months (40%), and was detectable by 4 to 6 years (17%). A few (4 to 5%) of adolescents and adults were positive for the antibody.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325026     DOI: 10.1111/j.1348-0421.1992.tb02047.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  10 in total

Review 1.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Frequent detection of the human herpesvirus 6-specific genomes in the livers of children with various liver diseases.

Authors:  Y Ozaki; H Tajiri; K Tanaka-Taya; S Mushiake; A Kimoto; K Yamanishi; S Okada
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

3.  An immunoblot assay for detection of immunoglobulin M antibody to human herpesvirus 6.

Authors:  S LaCroix; J A Stewart; M E Thouless; J B Black
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

4.  Detection of human herpesvirus 6 DNA in serum by a microplate PCR-hybridization assay.

Authors:  C Osiowy; I Prud'homme; M Monette; S Zou
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

5.  Real-time quantitative PCR for human herpesvirus 6 DNA.

Authors:  G Locatelli; F Santoro; F Veglia; A Gobbi; P Lusso; M S Malnati
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

Review 6.  Immune response to HHV-6 and implications for immunotherapy.

Authors:  Aniuska Becerra; Laura Gibson; Lawrence J Stern; J Mauricio Calvo-Calle
Journal:  Curr Opin Virol       Date:  2014-10-27       Impact factor: 7.090

7.  U94 of human herpesvirus 6 is expressed in latently infected peripheral blood mononuclear cells and blocks viral gene expression in transformed lymphocytes in culture.

Authors:  A Rotola; T Ravaioli; A Gonelli; S Dewhurst; E Cassai; D Di Luca
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

8.  U94 of human herpesvirus 6 inhibits in vitro angiogenesis and lymphangiogenesis.

Authors:  Arnaldo Caruso; Elisabetta Caselli; Simona Fiorentini; Antonella Rotola; Alberto Prandini; Emirena Garrafa; Elisa Saba; Giulio Alessandri; Enzo Cassai; Dario Di Luca
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-16       Impact factor: 11.205

Review 9.  Human Herpesvirus 6A Is a Risk Factor for Multiple Sclerosis.

Authors:  Wangko Lundström; Rasmus Gustafsson
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

10.  Successful treatment of human herpesvirus 6 encephalomyelitis in immunocompetent patient.

Authors:  Eric Denes; Laurent Magy; Karine Pradeau; Sophie Alain; Pierre Weinbreck; Sylvie Ranger-Rogez
Journal:  Emerg Infect Dis       Date:  2004-04       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.